134271-93-5

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-nitrophenyl)-2-propylidenehydrazine is used as a pharmaceutical intermediate for the synthesis of various organic compounds. Its unique structure allows it to serve as a key component in the development of new drugs and pharmaceuticals.
Used in Organic Synthesis:
In the field of organic chemistry, 1-(3-nitrophenyl)-2-propylidenehydrazine is used as a building block for creating a range of organic compounds. Its versatile structure makes it a valuable asset in the synthesis of complex molecules.
Used in Anti-tuberculosis Research:
1-(3-nitrophenyl)-2-propylidenehydrazine is also utilized in the research and development of potential anti-tuberculosis agents. Its biological activities are being studied to determine its effectiveness in combating tuberculosis, a significant global health concern.

Upstream product

• 51516-96-2 3-nitrophenylhydrazine hydrochloride 
• 123-38-6 propionaldehyde 
• 99-09-2 3-nitro-aniline 
• 619-27-2 3-nitrophenylhydrazine 

Downstream Products

• 133053-76-6 3-methyl-6-nitro-1H-indole 
• 873056-08-7 (2'-ethoxy-2-aminobiphenyl-4-yl)-carbamic acid tert-butyl ester 
• 134271-94-6 3-methyl-4-nitro-1H-indole 

Relevant academic research and scientific papers

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS

The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as well as pharmaceutical compositions containing such compounds. The compounds are useful in treating diseases and conditions mediated by TEAD, such as cancer.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.